Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
3.
Scand J Rheumatol ; 43(6): 512-8, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25204208

RESUMEN

OBJECTIVES: Recent findings suggest that autoimmune disorders predispose to a diminished capacity to taste and smell. This has been shown for patients with systemic lupus erythematosus as well as for patients with rheumatoid arthritis (RA). Granulomatosis with polyangiitis (GPA), with its particular manifestations in the upper respiratory tract, may therefore have an even higher impact on these senses. The aims of this study were to evaluate the gustatory and olfactory function in patients with GPA, to compare them to sex- and age-matched healthy controls, and to correlate these findings with their GPA disease severity. METHOD: Patients with established GPA were analysed by standardized assessments for gustatory and olfactory functions and examined for disease activity, stage of disease, and treatment. RESULTS: Forty-four GPA patients were tested for their chemosensory functions. Compared to age- and sex-matched healthy controls, GPA patients showed significantly decreased olfactory scores along with diminished scores for their gustatory functions. The diminished sense of smell in GPA patients correlated significantly with elevated C-reactive protein (CRP) values whereas the gustatory impairment correlated with the duration and extent of the disease. CONCLUSIONS: Our results indicate that olfactory and gustatory functions are significantly decreased in GPA. As the olfactory function of these patients was comparable to patients with RA, chemosensory impairment may not simply be a consequence of the involvement of the upper respiratory tract, but rather a common complication of systemic autoimmune diseases.


Asunto(s)
Granulomatosis con Poliangitis/fisiopatología , Olfato/fisiología , Gusto/fisiología , Adulto , Anciano , Femenino , Granulomatosis con Poliangitis/complicaciones , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos
4.
Dtsch Med Wochenschr ; 136(33): 1669-73, 2011 Aug.
Artículo en Alemán | MEDLINE | ID: mdl-21833888

RESUMEN

Adult-onset Still's disease is a rare inflammatory systemic disease. Cardinal symptoms/manifestations are fever, arthralgias or arthritis, myalgias, the typical skin rash, sore throat, hepatosplenomegaly, lymphadenopathy and serositis. Several other symptoms and organ involvements are possible. The clinical picture is variable with mild to life-threatening courses. The disease is self-limiting, intermittently active or chronic. Because of the lack of a defined diagnostic test the diagnosis of AOSD can only be made after exclusion of several differential diagnoses in particular of infectious, malignant and autoimmune origin. For therapy non-steroidal anti-inflammatory drugs, glucocorticoids, disease modifying antirheumatic drugs and biologics can be used.


Asunto(s)
Enfermedad de Still del Adulto/diagnóstico , Adulto , Antiinflamatorios no Esteroideos/uso terapéutico , Antirreumáticos/uso terapéutico , Productos Biológicos/uso terapéutico , Diagnóstico Diferencial , Glucocorticoides/uso terapéutico , Humanos , Pronóstico , Enfermedad de Still del Adulto/tratamiento farmacológico , Enfermedad de Still del Adulto/etiología
5.
Dtsch Med Wochenschr ; 129(23): 1308-12, 2004 Jun 04.
Artículo en Alemán | MEDLINE | ID: mdl-15179590

RESUMEN

BACKGROUND AND OBJECTIVE: Adult-onset Stills disease (AOSD) is a rare entity. The course of the disease can be mild or severe, acute or chronic. The intention of this survey was to evaluate the longterm efficacy of TNF blockade in patients with severe and active AOSD. PATIENTS AND METHODS: Eight patients with the diagnosis of AOSD, according to the diagnostic criteria developed by Yamaguchi in 1992, and pretreatment with either high dosage steroid or more intensive immunosuppressive therapy were treated with infliximab in a dosage of 3 - 5 mg/kg at time pointsduring week 0, 2 and 6. Later on, the treatment regimen was adapted to the individual needs of the patients. The follow-up period was between one and five years. RESULTS: Seven patients responded to treatment with infliximab. Symptoms like fever, arthralgia, hepato-splenomegaly and serological parameters instantly improved. Five of these patients remained in remission over years after discontinuation of therapy. One of the responding patients needed permanent intensive treatment with TNF-blockers to control his severe chronic arthritis. Three patients experienced infusion reactions. One responding patient was therefore switched to etanercept and kept on this therapy. The one patient, who had not responded to infliximab also had no benefit from consecutive treatment with etanercept or adalimumab. CONCLUSION: Anti-TNF therapy can have a lasting beneficial effect on the course of AOSD. Five of eight patients remained in remission even after termination of therapy.


Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Antirreumáticos/uso terapéutico , Enfermedad de Still del Adulto/tratamiento farmacológico , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Adalimumab , Adulto , Anticuerpos Monoclonales/farmacología , Anticuerpos Monoclonales Humanizados , Antirreumáticos/farmacología , Etanercept , Femenino , Humanos , Inmunoglobulina G/farmacología , Inmunoglobulina G/uso terapéutico , Infliximab , Masculino , Persona de Mediana Edad , Receptores del Factor de Necrosis Tumoral/uso terapéutico , Resultado del Tratamiento
6.
Br J Dermatol ; 144(3): 587-9, 2001 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-11260020

RESUMEN

BACKGROUND: In inflamed skin, keratinocytes and inflammatory cells both produce large amounts of tumour necrosis factor (TNF) -alpha, a cytokine with broad effects that are relevant to inflammation. Blockade of this proinflammatory cytokine by a monoclonal anti-TNF-alpha antibody might be effectively used in the treatment of inflammatory skin diseases. OBJECTIVES: To gather information about the efficacy of an anti-TNF-alpha antibody (infliximab) in the treatment of skin lesions of psoriatic arthritis. METHODS: Six patients with progressive joint disease and psoriatic skin lesions unresponsive to methotrexate therapy were treated with anti-TNF-alpha antibody. The Psoriasis Area and Severity Index was determined before and 10 weeks after initiation of therapy. RESULTS: Improvement of psoriatic skin lesions was observed in all patients. In addition, a marked improvement of the joint disease was noted. CONCLUSIONS: Therapy with anti-TNF-alpha antibody may be an effective treatment regimen for both psoriatic arthritis and psoriatic skin lesions.


Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Antirreumáticos/uso terapéutico , Fármacos Dermatológicos/uso terapéutico , Psoriasis/terapia , Artritis Psoriásica/terapia , Progresión de la Enfermedad , Resistencia a Medicamentos , Humanos , Infliximab , Metotrexato/uso terapéutico , Psoriasis/patología , Índice de Severidad de la Enfermedad , Factor de Necrosis Tumoral alfa/inmunología
7.
Eur J Med Res ; 5(8): 323-8, 2000 Aug 18.
Artículo en Inglés | MEDLINE | ID: mdl-10958764

RESUMEN

The heterozygous 32 base pair deletion of the chemokine receptor 5 (Delta32CCR5) has been associated with a more benign course of HIV-1-infection. To study the influence of Delta32CCR5 on the response to antiviral therapy we analyzed the presence of Delta32CCR5 by PCR in PBMC from 107 randomly selected HIV-1-infected patients treated with HAART for at least three months. 24 of 107 patients were heterozygous for Delta32CCR5 (22.4%). Before initiation of HAART Delta32CCR5 heterozygous patients (d/w) did not differ from homozygous CCR5 wild-type patients (w/w) regarding viral load and CD4 counts. After a median treatment time on HAART of 17.5 months (d/w, range 6-31 months, p = n.s.) or 19 months (w/w, range 3-33 months) all 24 patients (100%) with the Delta32CCR5 mutation, but only 58/83 patients (69.9%) with wild-type CCR5 showed a suppression of HIV-1-viremia below 500 copies/ml (p = 0.0020). Furthermore, 20/24 (83.3%) of the Delta32CCR5 heterozygous patients achieved CD4 counts above 200/microliter, but only 57/83 (68.7%) of the patients homozygous for CCR5 wild-type (p = 0.011). Our data indicate that the presence of heterozygous Delta32CCR5 is associated with a better response to HAART suggesting that therapeutic strategies targeting CCR5 could be of value for a sustained suppression of HIV-1 by HAART.


Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/tratamiento farmacológico , Síndrome de Inmunodeficiencia Adquirida/genética , Fármacos Anti-VIH/uso terapéutico , Didesoxinucleósidos/uso terapéutico , VIH-1 , Receptores CCR5/genética , Alelos , Estudios de Cohortes , Farmacorresistencia Microbiana/genética , Femenino , Humanos , Lamivudine/uso terapéutico , Masculino , Zidovudina/uso terapéutico
8.
Plant Cell Rep ; 19(5): 500-503, 2000 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-30754890

RESUMEN

Rooted regenerated shoots obtained from leaf and nodal segments of Rosmarinus officinalis were grown on a basal nutrient medium for 9 weeks. The regenerants were shown by means of HPLC and mass spectrometry to contain carnosic acid, a diterpenoid with antioxidant and medicinal properties. Five-week-old nodular green callus also contained carnosic acid, whereas non-green, undifferentiated callus maintained in the dark did not.

11.
Dev Comp Immunol ; 20(6): 393-406, 1996.
Artículo en Inglés | MEDLINE | ID: mdl-9040982

RESUMEN

Coiling phagocytosis has been observed previously only by chance, and there has been no systematic investigation of this uptake mechanism. Therefore, a comparative electron microscopical study was performed. Different human and murine cell populations, phagocytes from various vertebrate and invertebrate species, and predatory amoebae were incubated with Borrelia burgdorferi, one of the microbes known to induce coiling phagocytosis, to study the uptake mechanisms used. In this model, coiling phagocytosis was observed with both vertebrate and invertebrate species but not with amoebae. With cells from humans and mice, this uptake mechanism was restricted to phagocytic cells of myeloid origin. The coiled membrane gaps did not give rise to phagosomes; instead, membrane fusion was followed by membrane dissipation. Thus, coiling of B. burgdorferi apparently is an alternative uptake mechanism used by metazoan phagocytes, involving special membrane processing. However, coiling phagocytosis may show different features with different microbes.


Asunto(s)
Fagocitos/fisiología , Fagocitosis/fisiología , Animales , Grupo Borrelia Burgdorferi/ultraestructura , Línea Celular , Entamoeba histolytica/ultraestructura , Hartmannella/ultraestructura , Humanos , Macrófagos Peritoneales/fisiología , Macrófagos Peritoneales/ultraestructura , Ratones , Fagocitos/ultraestructura , Fagosomas/fisiología , Fagosomas/ultraestructura , Filogenia
12.
Hum Genet ; 89(2): 204-6, 1992 May.
Artículo en Inglés | MEDLINE | ID: mdl-1587532

RESUMEN

We present the results of an international collaborative study aimed at estimating the ratio of male to female mutation rates in Duchenne muscular dystrophy based on the method of C. Müller and T. Grimm. With a sample size of 295, this ratio is found to be very close to 1, thus giving evidence for equal mutation rates in males and females in Duchenne muscular dystrophy.


Asunto(s)
Distrofias Musculares/genética , Southern Blotting , Europa (Continente) , Femenino , Humanos , Masculino , Matemática , Mutación/genética , Factores Sexuales , Estados Unidos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA